HEARTFLOW INC SEC Filings

Heartflow, Inc. furnished an investor presentation in connection with an upcoming investor conference. The company posted the presentation on its website and attached it as Exhibit 99.1 to this report. The materials are provided under Regulation FD, and the company states that the information is being furnished, not filed, meaning it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities filings unless specifically referenced.

Heartflow, Inc. director Mr. Lightcap reported buying 40,000 shares of Heartflow common stock on 12/16/2025 in an open market purchase at a weighted average price of $26.342 per share. After this transaction, he holds 40,000 shares directly. The filing also lists additional indirect beneficial ownership through affiliated investment entities, including 4,615,542 shares held by HCPCIV 1, LLC, 833,075 shares held by HealthCor Partners Fund II, L.P., and 1,248,939 shares held by HealthCor Partners Fund, L.P., for which he is a controlling member and disclaims beneficial ownership beyond his economic interest.

HeartFlow, Inc. (HTFL) disclosed a routine insider transaction by its Chief Executive Officer and Director on 11/07/2025. The filing reports 1,339 shares of common stock reflected as a code F transaction at $32.56 per share, representing shares retained by the issuer to satisfy income tax withholding upon the vesting and net settlement of previously reported RSUs.

Following this administrative withholding event, the reporting person beneficially owns 431,909 shares, held directly.

HeartFlow, Inc. (HTFL) reported an insider transaction by its Chief Financial Officer on a Form 4. On 11/07/2025, the officer had 471 shares of common stock withheld/disposed at $32.56 under transaction code F, which reflects shares retained by the company to satisfy tax withholding upon the vesting and net settlement of previously reported RSUs. Following this event, the officer beneficially owns 144,912 shares directly.

Heartflow, Inc. filed a Form 4 reporting a tax-related share withholding from an RSU vesting. On 11/07/2025, 81 shares of common stock were withheld by the issuer at $32.56 per share under transaction code F.

The reporting person is an officer (Chief Accounting Officer, VP) and now directly holds 10,115 shares following the transaction. Code F reflects shares retained to satisfy income tax withholding obligations on previously reported RSUs, rather than an open-market sale.

Heartflow, Inc. reported Q3 2025 results. Revenue was $46,276 thousand with gross profit of $35,415 thousand. Operating loss was $15,099 thousand, and net loss was $50,855 thousand, driven in part by a $32,117 thousand increase in the fair value of the common stock warrant liability and a $6,360 thousand loss on extinguishment of debt.

The company completed its IPO on August 11, 2025, selling 19,166,667 shares at $19.00 per share for gross proceeds of approximately $364.2 million (net cash inflow of $332,784 thousand). All redeemable convertible preferred stock converted into 51,226,348 common shares, and 6,470,743 shares were issued upon conversion of 2025 convertible notes. A 1‑for‑2.92 reverse stock split was effected on July 31, 2025.

As of September 30, 2025, cash and cash equivalents were $291,167 thousand; the prior term loan was fully repaid (balance $0 versus $136,431 thousand at year‑end 2024). Shares outstanding were 85,158,719 as of October 31, 2025.

HeartFlow, Inc. filed an 8-K announcing it has furnished a press release detailing its financial results for the quarter ended September 30, 2025. The release is attached as Exhibit 99.1 and provides the company’s Q3 2025 performance update.

The information under Item 2.02 and Item 9.01 is furnished, not filed, under the Exchange Act, meaning it is not subject to Section 18 liability and is not incorporated by reference unless specifically stated. The filing confirms Nasdaq-listed ticker HTFL and Emerging Growth Company status.

HeartFlow, Inc. (HTFL) reported interim financial and operational disclosures reflecting a recent reverse stock split, significant financing activity and continuing operating losses. The company completed an IPO that raised approximately $364.2 million gross proceeds (before underwriting discounts and estimated offering expenses). As of June 30, 2025, cash and cash equivalents were $80.2 million versus $51.4 million at December 31, 2024, and the company had an accumulated deficit of approximately $1.0 billion. The company issued 2025 Convertible Notes totaling $98.3 million with embedded derivative features and maintains a 2024 Term Loan with an effective interest rate of 15.2% as of June 30, 2025. The 2024 Credit Agreement contains collateral, liquidity and trailing net sales covenants, including a minimum liquidity requirement reduced to $15.0 million and a rising minimum twelve-month net sales covenant up to $110.0 million. Management states that, together with expected customer revenue and IPO proceeds, available liquidity is sufficient to fund planned operations for at least the next 12 months from the date the condensed consolidated financial statements were available to be issued.

Heartflow, Inc. released preliminary, unaudited results for the three months ended June 30, 2025, in connection with an investor presentation at a healthcare conference. The company expects revenue of approximately $43.4 million, a gross margin of about 75.5%, and operating expenses near $46.5 million.

Heartflow also reports cash and cash equivalents of roughly $80.2 million as of June 30, 2025. This cash figure excludes the estimated $333.0 million of net proceeds from its August 11, 2025 initial public offering and the repayment of amounts outstanding under a credit agreement, including $114.1 million of principal as of June 30, 2025 plus accrued interest and fees.

The company notes that these figures are preliminary and unaudited and may change when it files its Form 10-Q for the quarter ended June 30, 2025.